Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 8:30 AM PT / 11:30 AM ET. Interested individuals can access a live and archived webcast on Pulmonx's website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, particularly its Zephyr® Endobronchial Valve, which received FDA pre-market approval as a breakthrough device. The Zephyr Valve is available in over 25 countries and has been used in more than 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) published long-term follow-up data from the IMPACT Study, showcasing the Zephyr® Valve's effectiveness for patients with severe COPD/emphysema and homogenous disease distribution. The study highlights significant benefits over 12 months, including improved lung function (FEV1), increased quality of life (SGRQ), enhanced exercise capacity (6MWD), and reduced hyperinflation. This minimally invasive treatment is the only FDA-approved option for this patient group, providing much-needed relief where traditional medications fail.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q2 2021 financial results on August 3, 2021, after the market closes. A conference call for this announcement will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 5682784. Pulmonx is a leader in minimally invasive treatments for severe lung disease, notably with its Zephyr Endobronchial Valve, used to treat over 20,000 patients globally.
Pulmonx Corporation (Nasdaq: LUNG) presented long-term data from the TRANSFORM study at the ATS 2021 International Conference, highlighting the sustained benefits of the Zephyr® Endobronchial Valve in patients with severe COPD/emphysema. The results indicate significant improvements in lung function, quality of life, and exercise capacity for up to 24 months post-treatment. This minimally invasive procedure, offering a viable alternative to major surgery, has treated over 20,000 patients globally, showcasing its acceptance in clinical guidelines.
Pulmonx Corporation (Nasdaq: LUNG) reported a 7% increase in worldwide revenue to $9.2 million for Q1 2021, with a gross margin improvement to 71.5%. U.S. revenue declined 5% to $4.3 million, while international revenue surged 20% to $5.0 million. Operating expenses rose 59% to $18.6 million, leading to a net loss of $12.0 million or $0.34 per share. The company raised its 2021 revenue outlook to $48-$50 million, representing 47%-53% growth year-over-year, despite ongoing COVID-19 uncertainties.
Pulmonx Corporation (Nasdaq: LUNG) announced the appointments of Michael Ryan as Vice President of Corporate Strategy and Business Development, David Lehman as General Counsel, and Mahtab Fatemi as Vice President of Regulatory Affairs and Quality Assurance. Ryan joins from Boston Scientific, bringing extensive experience in business development within the pulmonary sector. Lehman has nearly two decades of legal expertise in the medical device industry, while Fatemi has over 20 years of regulatory experience in medical devices and pharmaceuticals. These appointments aim to strengthen Pulmonx's market position.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 am PT / 11:00 am ET. A live and archived webcast will be available in the Investors section of the Pulmonx website.
The company’s Zephyr® Endobronchial Valve and related systems are crucial for treating severe emphysema/COPD patients. The Zephyr Valve is FDA-approved and used in over 25 countries, with more than 80,000 valves deployed.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q1 2021 financial results on May 4, 2021, after trading closes. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can listen in by calling (833) 614-1518 for domestic or (270) 823-1072 for international participants, using Conference ID: 6696232. Pulmonx is known for its minimally invasive treatments for lung diseases, including its Zephyr® Endobronchial Valve, which is available in over 25 countries and has been used in more than 80,000 devices to treat over 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) reported a full year 2020 revenue of $32.7M, a marginal increase of 0.4% year-over-year. U.S. revenue surged 51% to $16.2M, while international revenue fell 24% to $16.5M. The fourth quarter saw total revenue decline 5% to $9.8M. Operating expenses spiked 41% to $16.4M, resulting in a net loss of $9.3M. Looking ahead, the company expects 2021 revenue between $46M and $50M, reflecting 41%-53% growth.
Pulmonx Corporation (NASDAQ: LUNG) will release its financial results for Q4 and full year 2020 on March 2, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company focuses on minimally invasive treatments for severe emphysema, with its Zephyr® Endobronchial Valve approved by the FDA as a breakthrough device. The valve has been utilized in over 20,000 patients worldwide. For more details, visit their investor webpage.